Continue to site >
Trending ETFs

Loncar China BioPharma ETF

ETF
CHNA
Payout Change
Pending
Price as of:
$20.21 +0.22 +1.1%
primary theme
China Region Equity
CHNA (ETF)

Loncar China BioPharma ETF

Payout Change
Pending
Price as of:
$20.21 +0.22 +1.1%
primary theme
China Region Equity
CHNA (ETF)

Loncar China BioPharma ETF

Payout Change
Pending
Price as of:
$20.21 +0.22 +1.1%
primary theme
China Region Equity

Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$20.21

$5.43 M

15.00%

$3.03

0.79%

Vitals

YTD Return

-14.6%

1 yr return

-55.0%

3 Yr Avg Return

-2.0%

5 Yr Avg Return

N/A

Net Assets

$5.43 M

Holdings in Top 10

28.2%

52 WEEK LOW AND HIGH

$20.0
$15.75
$45.77

Expenses

OPERATING FEES

Expense Ratio 0.79%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 44.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund

Investment Style

China Region


Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$20.21

$5.43 M

15.00%

$3.03

0.79%

CHNA - Profile

Distributions

  • YTD Total Return -24.5%
  • 3 Yr Annualized Total Return -2.0%
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.05%
DIVIDENDS
  • Dividend Yield 15.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Loncar China BioPharma ETF
  • Fund Family Name
    Loncar Investments
  • Inception Date
    Aug 14, 2018
  • Shares Outstanding
    300000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Rafael Zayas

Fund Description

The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.


CHNA - Performance

Return Ranking - Trailing

Period CHNA Return Category Return Low Category Return High Rank in Category (%)
YTD -14.6% -22.2% 14.5% 54.26%
1 Yr -55.0% -55.0% 60.3% 100.00%
3 Yr -2.0%* -14.4% 27.8% 81.00%
5 Yr N/A* -7.7% 13.7% N/A
10 Yr N/A* 0.7% 11.9% N/A

* Annualized

Return Ranking - Calendar

Period CHNA Return Category Return Low Category Return High Rank in Category (%)
2021 -17.8% -52.5% 39.7% 52.07%
2020 31.3% -21.7% 138.4% 47.12%
2019 29.3% -1.9% 46.9% 44.90%
2018 N/A -52.1% -5.1% N/A
2017 N/A 1.1% 78.5% N/A

Total Return Ranking - Trailing

Period CHNA Return Category Return Low Category Return High Rank in Category (%)
YTD -24.5% -26.8% 24.5% 96.12%
1 Yr -55.0% -55.0% 60.3% 100.00%
3 Yr -2.0%* -14.4% 27.8% 81.00%
5 Yr N/A* -7.7% 13.7% N/A
10 Yr N/A* 0.7% 11.9% N/A

* Annualized

Total Return Ranking - Calendar

Period CHNA Return Category Return Low Category Return High Rank in Category (%)
2021 -17.8% -52.5% 39.8% 52.07%
2020 31.3% -21.7% 138.4% 47.12%
2019 29.3% -1.9% 47.0% 44.90%
2018 N/A -52.1% -5.0% N/A
2017 N/A 1.1% 78.5% N/A

CHNA - Holdings

Concentration Analysis

CHNA Category Low Category High CHNA % Rank
Net Assets 5.43 M 1.4 M 6.58 B 87.50%
Number of Holdings 61 6 961 47.37%
Net Assets in Top 10 1.53 M 706 K 4.22 B 93.23%
Weighting of Top 10 28.20% 6.6% 99.9% 94.74%

Top 10 Holdings

  1. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%
  2. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%
  3. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%
  4. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%
  5. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%
  6. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%
  7. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%
  8. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%
  9. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%
  10. Kintor Pharmaceutical Ltd Ordinary Shares 6.26%

Asset Allocation

Weighting Return Low Return High CHNA % Rank
Stocks
99.58% 0.00% 102.18% 28.36%
Cash
0.42% -2.18% 12.74% 69.92%
Preferred Stocks
0.00% 0.00% 0.00% 97.74%
Other
0.00% 0.00% 47.32% 97.74%
Convertible Bonds
0.00% 0.00% 0.15% 97.74%
Bonds
0.00% 0.00% 69.90% 97.76%

Stock Sector Breakdown

Weighting Return Low Return High CHNA % Rank
Healthcare
98.42% 0.00% 100.00% 2.26%
Communication Services
1.58% 0.00% 91.25% 69.92%
Utilities
0.00% 0.00% 89.15% 100.00%
Technology
0.00% 0.00% 94.15% 98.50%
Real Estate
0.00% 0.00% 99.07% 98.50%
Industrials
0.00% 0.00% 96.93% 100.00%
Financial Services
0.00% 0.00% 99.75% 98.50%
Energy
0.00% 0.00% 90.86% 100.00%
Consumer Defense
0.00% 0.00% 97.46% 98.50%
Consumer Cyclical
0.00% 0.00% 95.37% 98.50%
Basic Materials
0.00% 0.00% 92.11% 98.50%

Stock Geographic Breakdown

Weighting Return Low Return High CHNA % Rank
Non US
90.51% 51.72% 100.37% 90.98%
US
9.07% -0.04% 9.07% 0.75%

CHNA - Expenses

Operational Fees

CHNA Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.79% 0.09% 3.14% 66.18%
Management Fee 0.79% 0.09% 1.50% 50.00%
12b-1 Fee 0.00% 0.00% 1.00% 48.15%
Administrative Fee N/A 0.06% 0.26% N/A

Sales Fees

CHNA Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

CHNA Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 2.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

CHNA Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 44.00% 4.00% 278.00% 37.00%

CHNA - Distributions

Dividend Yield Analysis

CHNA Category Low Category High CHNA % Rank
Dividend Yield 15.00% 0.00% 15.00% 0.74%

Dividend Distribution Analysis

CHNA Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Annually Annually

Net Income Ratio Analysis

CHNA Category Low Category High CHNA % Rank
Net Income Ratio -0.05% -1.93% 4.74% 56.15%

Capital Gain Distribution Analysis

CHNA Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually

Dividend Payout History

View More +

CHNA - Fund Manager Analysis

Managers

Rafael Zayas


Start Date

Tenure

Tenure Rank

Jun 19, 2020

1.95

2.0%

Rafael Zayas, CFA, is Senior Vice President, Head of Portfolio Management and Trading at Vident Investment Advisory, LLC since June 2020. Mr. Zayas became SVP, Head of Portfolio Management and Trading in June 2020. From 2017 to 2020, he was a Senior Portfolio Manager – International Equity at Vident and has over 15 years of experience that includes managing international equity portfolios, including in emerging and frontier markets. Prior to joining Vident, he was a Portfolio Manager – Direct Investments for seven years at Russell Investments, a global asset manager, where he co-managed more than $4 billion in quantitative strategies across global markets, including the Russell Strategic Call Overwriting Fund, a mutual fund. Mr. Zayas also helped Russell Investments launch its sponsored ETF initiative and advised on index methodologies. Prior to joining Russell Investments, Mr. Zayas was a Portfolio Manager – Equity Indexing at Mellon Capital Management, where he managed assets for internationally listed global equity ETFs. Mr. Zayas graduated with a B.S. in Electrical Engineering from Cornell University and obtained a Certificate in Computational Finance and Risk Management from the University of Washington. He also attained the Chartered Financial Analyst designation in 2010.

Austin Wen


Start Date

Tenure

Tenure Rank

Jun 19, 2020

1.95

2.0%

Austin Wen, CFA has seven years of investment management experience. Mr. Wen is a Portfolio Manager at Vident, specializing in portfolio management and trading of equity portfolios and commodities based portfolios, as well as risk monitoring and investment analysis. Previously, Mr. Wen was an analyst for Vident Financial, working on the development and review of investment solutions. He began his career as a State Examiner for the Georgia Department of Banking and Finance. Mr. Wen obtained a BA in Finance from the University of Georgia and holds the Chartered Financial Analyst designation.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.07 28.32 3.64 0.25